Impact of Inflammatory Markers and Body Mass Index on TKI Toxicity in Patients With Non-Small Cell Lung Cancer Harboring an EGFR Mutation

被引：0
|
作者：
Runciman, T. [1 ]
Carracedo, C. [1 ]
Motta, R. [1 ]
Aliaga, C. [1 ]
机构：
[1] Clin Aliada, Lima, Peru
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
NLR; BMI; EGFR NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P76.12
引用
收藏
页码：S590 / S591
页数：2
相关论文
共 50 条
  • [1] Evaluation of TKI toxicity according to inflammatory markers and body mass index in patients with non-small cell lung cancer (NSCLC) harboring an EGFR mutation: A retrospective observational study.
    Runciman, Thanya
    Guerrero, Rodrigo Motta
    Macha, Carlos Aliaga
    Carracedo, Carlos F.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non-small cell lung cancer harboring EGFR mutation
    Kodama, Hiroaki
    Kenmotsu, Hirotsugu
    Kawabata, Takanori
    Notsu, Akifumi
    Yabe, Michitoshi
    Nishioka, Naoya
    Miyawaki, Eriko
    Miyawaki, Taichi
    Mamesaya, Nobuaki
    Kobayashi, Haruki
    Omori, Shota
    Wakuda, Kazushige
    Ono, Akira
    Naito, Tateaki
    Murakami, Haruyasu
    Takahashi, Toshiaki
    CANCER MEDICINE, 2021, 10 (21): : 7503 - 7513
  • [3] Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study
    Ono, Taihei
    Igawa, Satoshi
    Ozawa, Takahiro
    Kasajima, Masashi
    Ishihara, Mikiko
    Hiyoshi, Yasuhiro
    Kusuhara, Seiichiro
    Nishinarita, Noriko
    Fukui, Tomoya
    Kubota, Masaru
    Sasaki, Jiichiro
    Hisashi, Mitsufuji
    Katagiri, Masato
    Naoki, Katsuhiko
    THORACIC CANCER, 2019, 10 (04) : 880 - 889
  • [4] Bevacizumab to combat EGFR-TKI resistance in a patient with advanced non-small cell lung cancer harboring an EGFR mutation: A case report
    Wang, Zhiyi
    Zhou, Pu
    Li, Guanghui
    ONCOLOGY LETTERS, 2016, 12 (01) : 356 - 360
  • [5] Long Term Therapeutic Plan for Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutation
    Jang, Seung Hun
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2014, 76 (01) : 8 - 14
  • [6] Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation
    Satoshi Igawa
    Masashi Kasajima
    Mikiko Ishihara
    Michiko Kimura
    Yasuhiro Hiyoshi
    Hideyuki Niwa
    Seiichiro Kusuhara
    Shinya Harada
    Maiko Asakuma
    Sakiko Otani
    Ken Katono
    Jiichiro Sasaki
    Noriyuki Masuda
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 939 - 946
  • [7] Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation
    Igawa, Satoshi
    Kasajima, Masashi
    Ishihara, Mikiko
    Kimura, Michiko
    Hiyoshi, Yasuhiro
    Niwa, Hideyuki
    Kusuhara, Seiichiro
    Harada, Shinya
    Asakuma, Maiko
    Otani, Sakiko
    Katono, Ken
    Sasaki, Jiichiro
    Masuda, Noriyuki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (05) : 939 - 946
  • [8] The Impact of Systemic Inflammatory Markers on EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)
    Wangsubtawee, S.
    Trachu, N.
    Incharoen, P.
    Jinawath, N.
    Cheyasawan, P.
    Monnamo, N.
    Muntham, D.
    Sanvarinda, P.
    Chairoungdua, A.
    Khiewngam, K.
    Ngodngamtaweesuk, M.
    Amponnavarat, S.
    Reungwetwattana, N.
    Sirachainan, E.
    Dejthevaporn, T. S.
    Chansriwong, P.
    Reungwetwattana, T.
    Thamrongjirapat, T.
    Lumjiaktase, P.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S449 - S449
  • [9] Impact of EGFR mutation analysis in non-small cell lung cancer
    Yamamoto, Hiromasa
    Toyooka, Shinichi
    Mitsudomi, Tetsuya
    LUNG CANCER, 2009, 63 (03) : 315 - 321
  • [10] Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation
    Kawamura, Takahisa
    Kenmotsu, Hirotsugu
    Kobayashi, Haruki
    Omori, Shota
    Nakashima, Kazuhisa
    Wakuda, Kazushige
    Ono, Akira
    Naito, Tateaki
    Murakami, Haruyasu
    Mori, Keita
    Endo, Masahiro
    Takahashi, Toshiaki
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (01) : 194 - 201
12345